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Abstract
Cynomolgus macaques are an increasingly important nonhuman primate model for HIV vac-
cine research. SIV-free animals without pre-existing anti-SIV immune responses are gener-
ally needed to evaluate the effect of vaccine-induced immune responses against the
vaccine epitopes. Here, in order to select such animals for vaccine studies, we screened
108 naïve female Mauritian cynomolgus macaques for natural (baseline) antibodies to SIV
antigens using a Bio-Plex multiplex system. The antigens included twelve 20mer peptides
overlapping the twelve SIV protease cleavage sites (-10/+10), respectively (PCS peptides),
and three non-PCS Gag or Env peptides. Natural antibodies to SIV antigens were detected
in subsets of monkeys. The antibody reactivity to SIV was further confirmed by Western blot
using purified recombinant SIV Gag and Env proteins. As expected, the immunization of
monkeys with PCS antigens elicited anti-PCS antibodies. However, unexpectedly, antibod-
ies to non-PCS peptides were also induced, as shown by both Bio-Plex and Western blot
analyses, while the non-PCS peptides do not share sequence homology with PCS peptides.
The presence of natural and vaccine cross-inducible SIV antibodies in Mauritian cynomol-
gus macaques should be considered in animal selection, experimental design and result
interpretation, for their best use in HIV vaccine research.
Introduction
Simian immunodeficiency virus (SIV) infection of nonhuman primates (NHPs) is currently
the best animal model to test HIV vaccine strategies or study HIV pathogenesis [1–11].
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Traditionally, rhesus macaques (Macaca mulatta) are the favorite choice among NHPs in HIV
vaccine studies [1–5]. A wealth of knowledge has been accumulated for this species regarding
SIV-host interaction, viral and cellular dynamics following SIV infection, genetics and physiol-
ogy [6, 7]. However, the availability of rhesus macaques has been greatly reduced due to a ban
of their export from India and most other south Asian countries [6, 12]. Cynomolgus
macaques (Macaca fascicularis) have become by far the most internationally traded NHP for
laboratory experiments [6]. In comparison to rhesus macaques, several characteristics make
cynomolgus macaques a particularly useful animal model for HIV vaccine research, apart
from their availability. SIV infection of cynomolgus macaques leads to a disease pattern that
closely mimics that of human HIV infection, with lower peak and set-point viral loads and
slower disease progression typical of human AIDS [6].
The largest laboratory supply of cynomolgus macaques is available from the island of Mau-
ritius. The Mauritian cynomolgus macaques descended from a small group of founder animals
and are characterized by high genetic homogeneity with much fewer MHC haplotypes and
alleles [6, 7, 13–15]. This helps reduce outbred variability between animals and thus reduces
the number of animals needed to achieve statistical power, making them practical for HIV vac-
cine studies [7].
Commonly, vaccine studies are carried out in specific pathogen-free animals to rule out the
impact of on-going infection or pre-existing immune responses in order to soley evaluate the
vaccine efficacy absent of confounding variables. This may require screening larger numbers
of animals than those used in the vaccine experiments. Published reports from HIV vaccine
studies using NHPs generally failed to provide details of the cohort screening. However, such
information is valuable and can serve to guide future vaccine projects. A practical concern in
vaccine studies is that a large number of animals are required to achieve statistical power. The
information of expected frequency of animals with pre-existing infection or immune
responses is important for estimating the starting number of animals to be screened. Here, we
report the levels and frequencies of natural antibodies to SIV antigens among a population of
108 Mauritian cynomolgus macaques. These SIV antigens include peptides surrounding the
twelve protease cleavage sites [16] (PCS peptides) and three non-PCS Gag or Env peptides of
SIVmac239 [17–19]. In addition, we observed that vaccination of Mauritian cynomolgus
macaques with PCS antigens not only elicited antibodies to the PCS peptides, but also cross-
induced antibodies to non-PCS peptides, while the non-PCS peptides share no sequence
homology with the PCS peptides. This suggests that a vaccine could elicit immune responses
targeting SIV antigens other than those directly from the vaccine. These novel antibody
responses need to be taken into consideration in HIV vaccine projects using Mauritian cyno-
molgus macaques.
Materials and methods
Experimental animals and ethics statement
108 female Mauritian cynomolgus macaques (Macaca facicularis) from Bioculture (Mauritius)
Ltd were involved in this study, including groups of 94 colony-bred animals and 14 capture-
bred animals. From the former group 94 animals only their plasma samples were purchased
for in vitro antibody analysis, without any physical involvement of these animals in this study.
Only the latter group 14 animals were physically involved in the animal work of this study and
were used for immunization and viral challenge experiments. The immunization and viral
challenge experiments are detailed below as part of Materials and Methods. The animal work
was conducted in accordance with Canadian Council on Animal Care guidelines and the Ani-
mal Use Document was approved by the Canadian Sciences Centre for Human and Animal
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Health Animal Care Committee (protocol number: H-12-014R2). The humane care of animals
was performed as previously described [20]: "Animals were double housed in standard non-
human primate cages, received standard primate feed as well as fresh fruit and enrichment
daily, and had continual access to water. Temperature (19–24˚C), humidity (45–60%) and
light (approximately 323 lux) were monitored and maintained within recommended limits,
the light/dark cycle was maintained at 12 hour split. Environmental enrichment was provided.
Animals were observed twice daily by the PI, a co-investigator, or the veterinary staff for signs
of clinical illness”. The cages meet CCAC guidelines for primate housing. The dimensions of
the one-over-one primate cages used measure at 38 inches wide, 49 inches deep and 101 inches
high. Anesthesia was administered to alleviate suffering by injection with Ketamine Hydro-
chloride at a dosage of 10 mg/kg (i.m., using 23–25 gauge, 3/8-1 inch needles) prior to phlebot-
omy or intravaginal viral challenge. Animals were sacrificed at the end of the study or in
situations of multiple systemic consequences from simian AIDS, such as wasting (weight loss),
diarrhea, generalized lymphadenopathy, pneumonia, encephalitis, vascular thrombosis and
secondary infections coupled with complete anorexia for more than two days resulting in
acute weight loss of more than 20%. Following induction of deep anesthesia with Ketamine
Hydrochloride at a dosage of 25–50 mg/kg (using 23–25 gauge, 3/8-1 inch needles), euthanasia
was performed by terminal bleeding (femoral and/or intracardiac exsanguination). Sedation
was maintained by inhalation of Isoflurane 2.5–3.5% by mask in 100% oxygen.
The SIV antigens
During HIV or SIV replication, each of the 12 protease cleavage reactions is essential for the
production of a functional viral particle [16]. A novel vaccine strategy targeting the protease
cleavage sites (PCS) has been suggested by our studies [16, 21] and is being evaluated using
Mauritian cynomolgus macaque SIV infection model. As part of the ongoing work, we used
PCS peptide antigens (along with non-PCS peptides) to screen for potentially pre-existing nat-
ural antibody responses in Mauritian cynomolgus macaques, while no natural immune
response screen study has been reported in these animals. Specifically, the SIV antigens used
in this study were twelve 20mer peptides overlapping the twelve PCS (-10/+10) and three non-
PCS Gag or Env peptides, derived from SIVmac239 [17–19] (Table 1). The sequences of all
these peptides were confirmed to be specific for SIV by NCBI protein BLAST and are con-
served among multiple SIV strains (Data not shown). No sequence homology was shared
between PCS versus non-PCS peptides (Figure A in S1 File).
Bio-Plex multiplexed antibody assay
Plasma IgG antibodies to SIV antigens were quantified by largely following the previously pub-
lished protocols [22, 23] with slight modifications. Briefly, 20 μg of antigen peptide (synthe-
sized by Genscript, Piscataway, NJ) was coupled to 1.25 x 106 Bio-Plex Pro™ Magnetic COOH
Beads (Bio-Rad) using a Bio-Plex Amine Coupling Kit (Bio-Rad). 50 μl plasma (1:80 diluted)
was incubated with 2,500 beads/antigen type. SIV-specific IgG was detected with phycoery-
thrin-labelled mouse anti-monkey IgG (Southern Biotech, Birmingham, AL) at 5 μg/ml. Bead
fluorescence intensities were acquired on the Bio-Plex 200 system (Bio-Rad) and converted to
concentrations based on estimation using a PCS2 monoclonal antibody (National Microbiol-
ogy Laboratory, Canada) as standard.
Viral challenge and antiretroviral drug treatment (ARV)
Five macaques (previously immunized with a vesicular stomatitis virus vaccine vector,
rVSVwt) were intravaginally challenged with 1000 TCID50 SIVmac251 (Desrosiers 2010-Day
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8 viral stock, provided by Drs. Jon Warren, and Nancy Miller, Vaccine Research Program,
NIH). The challenge was repeatedly carried out (ranging two to four times) in each animal
until positive plasma viral load (VL) was detected. The VL was then monitored weekly
throughout the experiment. Daily antiretroviral drug treatment with a combination of FTC
(50mg/kg body weight), PMPA (20mg/kg) and raltegravir (10mg/kg) was initiated 25 weeks
after SIVmac251 infection. Plasma IgG antibodies to SIV peptides were quantified by Bio-Plex
multiplexed antibody assay for time points of weeks 0 and 5 post ARV initiation.
Viral load assay
This was conducted following a previously published protocol [20].
Indirect enzyme-linked immunosorbent assay (ELISA) quantification of
antibodies to vesicular stomatitis virus (VSV) and Zaire Ebola virus
(ZEBOV)
96-well ELISA plates were coated with 100 μl of 1 μg/ml purified VSV or ZEBOV [24]
(National Microbiology Laboratory, Canada) as capture antigens at 4˚C overnight. Plate wash-
ing along the ELISA procedure was performed with PBS containing 0.1% Tween20 and block-
ing was with 5% skim milk in PBS containing 0.1% Tween20. Monkey plasmas diluted at 1:100
and a following HRP-conjugated goat anti-human IgG secondary antibody (Kirkegaard &
Perry Laboratories, catalog number 074–1006) diluted at 1:2000 were used, respectively, both
at 37˚C for 1 hour. After a final incubation with a TMB substrate solution (ThermoFisher Sci-
entific, catalog number 34028) at 37˚C for 30 minutes, optical density (OD) values were read
at 650 nm.
MHC genotyping
The Cynomolgus macaque MHC haplotype typing was conducted by Wisconsin Nonhuman
Primate Research Centre Genetics Services [25, 26].
Table 1. SIV antigen peptides used in antibody screening.













SIVgag No cleavage VGDHQAAMQIIRDIINEEAADWDL
SIVenv1 No cleavage NVTESFDAWNNTVTEQAIEDVWQLFETSIRPCVKLSP
SIVenv2 No cleavage RVTAIEKYLKDQAQLNAWGCAFRQVCHTTVPWPNA
https://doi.org/10.1371/journal.pone.0186079.t001
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Construction of recombinant VSV vectors encoding the nucleotide
sequences of the 12 protease cleavage sites (rVSVpcs vectors)
The sequence of Simian immunodeficiency virus strain SIVmac239 was retrieved from the Los
Alamos National Laboratory HIV database (http://www.hiv.lanl.gov). The nucleotide sequences
encoding 20 amino acids (10 amino acids flanking each side of the cleavage site) overlapping
each of the 12 PCS [MA(p15)/CA(p27), CA(p27)/p2, p2/NC(p8), NC(p8)/p1, p1/p6gag,
NCgag-pol/TFP, TFP/NCgag-pol, p6gag-pol/Protease(p10), Protease(p10)/ RT(p66), RT(p51)/
RNase(p15), RNase(p15)/integrase (p31) and Nef] (Table 1) were synthesized and cloned in a
Blue Heron pUC(-)MCS plasmid (BlueHeron Biotechnology, Bothell, WA, USA). Each PCS
sequence was flanked by an upstream MluI restriction site (AAACGCGT), Kozak sequence
(GCCACC), start codon, and downstream stop codon and AvrII restriction site (CCTAGGTT).
The PCS coding fragment was then sub-cloned into a modified Vesicular Stomatitis Virus
(VSV) vector, a gift to Gary Kobinger from John Rose, Yale University School of Medicine. The
modified VSV plasmid (pATX VSV-G) expresses the positive-strand RNA complement of the
VSV genome and can tolerate the addition of four foreign genes at four multiple cloning sites
(MCS #1–4). MCS#3 was identified to promote the highest expression levels of luciferase and
EGFP reporter genes by luciferase assays and FACS analysis (Wong 2011, personal communica-
tions). The pATX VSV-G vector contained in order: bacteriophage T7 promoter (T7P), the
VSV leader, nucleoprotein (N), phosphoprotein (P), matrixprotein (M), glycoprotein (G) (in
MCS#4), polymerase (L), ampicillin resistance gene (AmpR), hepatitis delta virus ribozyme and
the T7 terminator sequence. Sub-cloning of PCS coding sequences into MCS#3 of pATX
VSV-G was performed using the following procedure. pATX-VSV-G vector and Blue Heron
pUC(-)MCS plasmids containing each of the twelve PCS were double digested with AvrII and
MluI (New England BioLabs, ON, Canada). 20 ul of each digested product was electrophoresed
in a 1% low-melt agarose gel (Invitrogen, CA, USA) and stained with SYBR1 Gold (Invitrogen,
CA, USA) for 15 minutes. The linearized pATX VSV-G vector band was excised and purified
using the QIAquick Gel Extraction kit (Qiagen, USA). The PCS DNA band from each digested
Blue Heron pUC(-)MCS plasmid was excised and purified using the QIAEX II Agarose Gel
Extraction kit (Qiagen, USA). Each of the 12 PCS fragments was cloned into the digested pATX
VSV-G vector by ligation with T4 DNA ligase (Invitrogen, CA, USA). Ligated plasmids were
transformed into One Shot1 Top10 cells (Invitrogen, CA, USA) and purified following the
Endofree Plasmid Maxi purification kit (Qiagen, USA). All recombinant VSV plasmids were
verified by sequencing (DNA Core Facility, National Microbiology Laboratory, Canada) using
BigDye Terminator Cycle Sequencing Ready Reaction kits (Applied Biosystems, Foster City,
CA) and Prism 3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA).
rVSVpcs virus generation
HEK293T and VeroE6 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% fetal bovine serum (FBS), penicillin (100 U/ml), streptomycin (100 μg/ml), L
glutamine (2mM) (Invitrogen, CA, USA). Cells were transfected with rVSVpcs plasmid (2 μg)
and support plasmids (2 μg of T7, 0.5 μg of N, 0.3 μg of L and 1.3 μg of P) with Lipofectamine
2000 (Invitrogen, CA, USA) according to manufacturer’s protocols. Cells were incubated at
37˚C/5% CO2 until the transfected cells displayed cytopathetic effect compared to negative
control cells. Rescued rVSVs were then passaged on VeroE6 cells to obtain a virus stock. Virus
stock was purified and concentrated by ultracentrifugation through a 20% sucrose cushion in
a Beckman XPN-80 ultracentrifuge at 27,000 RPM, 4˚C for 2 hours. The final pellet was resus-
pended in DMEM and stored at -80˚C. Purified rVSVpcs stock was plaque titrated with
VeroE6 cells.
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Packaging of PCS peptides into nanoparticles (NANOpcs)
Twelve 20mer peptides overlapping the PCS of SIVmac239 were synthesized (GenScript) for
nanopackaging. The peptides were associated to a nanoparticle system formed by chitosan
(CS) and dextran sulfate (DS). Due to their opposite charges, it is possible to form nanoparti-
cles by a simple ionic interaction process under mild conditions. Briefly, the CS:DS nanoparti-
cles were formed spontaneously upon addition of 0.825 ml of an aqueous DS solution (1.875
mg/ml) to the same volume of an aqueous CS solution (0.625 mg/ml) under magnetic stirring.
For peptide encapsulation, the peptide was incorporated in the anionic (DS solution) or in the
cationic phase (CS solution) according to its isoelectric point (pI). Peptides with pI lower than
7, were dissolved in the anionic phase while the rest of the peptides were dissolved in the cat-
ionic phase. The peptide theoretical loading in nanoparticles was 9.6%. Each one of the pep-
tides was encapsulated separately, and then, a pool of loaded nanoparticles, containing 50 μg
of each peptide, was prepared in individual vials for a single administration. For an improved
conservation, the nanoparticles suspension in each vial, were incorporated in a cryoprotectant
solution (trehalose 5%, w/v) and submitted to a freeze-thaw cycle. The vials were frozen at
-80˚C overnight and then submitted to two sequential drying steps in a lyophilizer. The pri-
mary drying was carried out at -35˚C (40 h) under high vacuum, and then the second drying
step (8 h), in which the temperature gradually raised until +20˚C, forming an uniform dry
cake. To evaluate the effect of this operation over the formulation characteristics, loaded nano-
particles with each peptide, were freeze-dried with the same protocol and afterwards reconsti-
tuted with ultrapure water in order to analyze their size and polydispersity index (PdI). The
nanoparticles diameter and PdI were evaluated by diffraction laser spectroscopy and its surface
charge by electrophoretic mobility using a Zetasizer Nano ZS90 (Malvern Instruments, UK).
The morphology of the particles was evaluated by transmission electronic microscopy (TEM).
Ultrapure CS hydrochloride salt, having a molecular weight of around 125 kDa and an acetyla-
tion degree of 14% (Protasan UP Cl 113), was purchased from Novamatrix (Norway). The DS
with a molecular weight of about 14,500 Da was obtained from Sigma–Aldrich (Madrid,
Spain).
Immunization: PCS vaccination
Fourteen monkeys were immunized (i.m., right hind leg). Each of 8 monkeys in the vaccine
group received a total of 1.2×107 plaque forming units (pfu) of pooled rVSVpcs viral particles
(1×106 pfu for each of the 12 rVSVpcs). Each of the 6 monkeys in the control group received
1.2×107 pfu of rVSV wild type (rVSVwt). The monkeys were boosted at week 5, with PCS pep-
tides packaged in nanoparticles (NANOpcs) for vaccine group and water (NANO vehicle) for
control group, and boosted again at week 9, with rVSVpcs/NANOpcs for vaccine group and
rVSVwt/water for control group.
Enrichment of SIV peptide-specific antibodies
SIV peptides (synthesized by Genscript, Piscataway, NJ) were coupled to CarboxyLink cou-
pling gel (ThermoFisher Scientific, Rockford, IL; Catalog 20266) and used to enrich SIV pep-
tide-specific antibodies from crude monkey plasma. Total plasma antibodies were purified
using Pierce protein A/G agarose beads (ThermoFisher Scientific, Catalog 20422).
Western blot
SDS-PAGE was conducted following the NuPAGE Bis-Tris mini gel electrophoresis protocol
(Thermo Fisher Scientific, Waltham, MA). Purified recombinant SIV proteins (NIH AIDS
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Reagent Program), SIVmac251 Gag (Catalog 1845) and SIVmac239 Env (Catalog 2322) were
diluted in 1× NuPAGE LDS sample buffer (Thermo Fisher Scientific, Catalog NP0008) con-
taining 1× NuPAGE reducing agent (Thermo Fisher Scientific, NP0009) and heated at 70˚C
for 10 minutes. 10 μl molecular weight marker, Precision Plus protein Dual Color Standards
(Bio-Rad, 161–0374), Magic Mark XP Western Standard (Thermo Fisher Scientific, LC5602)
or Spectra™ Multicolor Broad Range Protein Ladder (Thermo Fisher Scientific, 26634), or 1 μg
SIV protein in 15 μl sample buffer was loaded onto a NuPAGE 4–12% Bis-Tris 1.0mm×10well
gel (Thermo Fisher Scientific, NP0321BOX) assembled in a mini gel tank (Thermo Fisher Sci-
entific, A25977). The buffer chambers were filled with 1×NuPAGE MES SDS running buffer
(Thermo Fisher Scientific, NP0002). NuPAGE™ Antioxidant (Thermo Fisher Scientific,
NP0005) was added to the running buffer of the upper (cathode) chamber at 400× dilution.
The electrophoresis was run at 200V for 35 minutes. Blotting was performed using iBlot gel
transfer device (Thermo Fisher Scientific, IB1001) and iBlot gel transfer nitrocellulose mini
stacks (Thermo Fisher Scientific, IB301002), according to the supplier’s protocol. Blotting
membranes were rinsed with wash buffer (PBS containing 0.1% Tween 20) and then blocked
with 5% skim milk in wash buffer at room temperature with shaking at 100 rpm. 3× wash of 5
minutes at room temperature with shaking was performed after blocking and between/after
antibody incubation steps. Two types of primary antibodies were used. To confirm if natural
SIV peptide-specific antibodies recognize authentic SIV proteins, antibodies enriched from
monkey plasma (as described above) were diluted at 1 μg/ml in antibody buffer (wash buffer
containing 0.5% skim milk). Control antibodies were protein A/G-purified total Ig from SIV
antibody-negative monkey plasma. To confirm if PCS vaccination-induced monkey antibodies
recognize authentic SIV proteins, monkey crude plasmas from time points of baseline or 1
week after PCS vaccination were diluted at 1:125 in antibody buffer. In both cases, the diluted
primary antibodies were incubated with membranes at 4˚C with shaking overnight. The sec-
ondary antibody, goat anti monkey IgG-HRP (Santa Cruz Biotechnology, sc-2458) was diluted
at 1:2000 in antibody buffer and incubated with membrane for 1 hour at room temperature
with shaking. Chemiluminescent detection was based on Pierce ECL Western blotting sub-
strate (Thermo Fisher Scientific, 32209) and carried out on a ChemiDoc XRS instrument
using Quantity One 4.6.9 software (Bio-Rad). The application setting was chemi Hi sensitivity,
no light 2×gain, 2×2 Bin and manual exposure for 5 minutes. To control sample loading, mem-
branes were stripped in Restore™ PLUS Western blot stripping buffer (Thermo Fisher Scien-
tific, 46428) for 15 minutes at room temperature with shaking and re-probed with standard
SIV antibodies. The standard SIV antibodies were a mixture of multiple clones of NIH AIDS
Reagent Program mouse monoclonal antibodies specific for SIV Gag or Env proteins. For
Gag, the antibodies include catalog numbers of 2320 and 2321, which were each 1:4,000
diluted. For Env, the antibodies include catalog numbers of 4669, 2695, 2319, 2696, 12224,
2317, 4670, 1403, 12223 and 1812, which were each 1: 20,000 diluted. The secondary antibody
in combination was goat anti-mouse IgG-HRP (Santa Cruz Biotechnology, sc-2005), used at
1:5,000 dilution. To quantify vaccine-induced changes in the levels of monkey plasma IgG
antibodies to SIV Gag or Env proteins, the SIV antibody levels were defined by normalizing
the band intensities in the initial monkey antibody blots to their counterparts in the re-probed,
mouse antibody blots.
Statistical analysis
Statistical analysis was performed using GraphPad Prism statistical software. Continuous vari-
ables were compared with Student’s t test; categorical variables were compared with Fisher’s
exact test.
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Results
Natural antibodies to novel SIV antigens are detected in naïve Mauritian
cynomolgus macaque populations
To prepare for a preclinical evaluation of a novel HIV vaccine strategy targeting the 12 viral
protease cleavage sites (PCS) using an intravaginal challenge model, we screened 108 ran-
domly selected, naïve female Mauritian cynomolgus macaques for potential natural antibodies
against SIV antigens, including 12 PCS peptides (our vaccine of interest) and 3 non-PCS Gag
and Env peptides (See Materials and methods for details). The macaques, 14 capture-bred and
94 colony-bred, had not been used in any previous SIV challenge or vaccination study before
the antibody screening. Using a Bio-Plex multiplexed antibody assay, we found that subsets of
animals had higher than background levels of antibodies (Fig 1 and Table A in S1 File). Since
these monkeys had not been previously infected with SIV or exposed to SIV antigens that
would induce SIV antibodies, we carefully validated the results obtained with the Bio-Plex
method. We used two other methods to verify whether these are anti-SIV antibodies. We first
tested whether these antibodies recognize authentic SIV proteins by Western blot analysis
using affinity-purified SIV peptide-specific antibodies from monkey plasma samples. The
results showed that these antibodies indeed recognized purified recombinant SIV Gag and
Env proteins (Fig 2). Next, we characterized antibody responses to these SIV peptide antigens
in the scenario of SIV infection (Fig 3). Five monkeys were experimentally infected with SIV-
mac251, followed by treatment with anti-retroviral drugs (ARV) FTC, PMPA and raltegravir
[27, 28]. We found that the levels of antibodies to PCS and non-PCS peptides were high before
ARV treatment, but were significantly decreased after ARV (Fig 3A) and the decrease of anti-
bodies to the SIV peptide antigens corresponded to the decrease of SIV viral load (Fig 3B). To
exclude the possibility that the reduction of anti-SIV antibody responses might be due to a
general impairment by ARV in the host antibody production function, we evaluated anti-
vesicular stomatitis virus (VSV) antibodies in these animals as they had previously been immu-
nized with a VSV vector (rVSVwt). We found that their anti-VSV antibody responses were
not inhibited by ARV (Fig 3C). Thus, a potential non-specific effect of ARV was ruled out.
Together, these results confirmed that the antibodies to PCS and non-PCS peptide antigens
are indeed anti-SIV antibodies.
Possible factors influencing the level of natural antibodies to SIV
antigens
Having observed the natural anti-SIV antibodies in Mauritian cynomolgus macaues, including
capture bred and colony bred animals, we asked whether environment or host factors influ-
ence the level of these antibodies. While these antibodies were detected in both the capture
bred and colony bred monkeys and the antibody variability showed similar patterns, the cap-
ture bred monkeys had higher levels of antibodies to PCS1, PCS7, PCS11 and SIVgag (Fig 4A).
This suggests that environmental factors may influence the magnitude of natural antibodies to
some SIV antigens. In addition, we observed host-specific patterns when the antibody levels to
all the SIV peptides were examined in individual monkeys (Table A in S1 File). Among impor-
tant host factors underlying immune responses and susceptibility or resistance to HIV/SIV
infection, the major histocompatibility complex (MHC) plays an important role in the initia-
tion and regulation of immune responses based on their ability to bind and present viral epi-
topes [7, 15, 19, 29]. We analyzed the MHC haplotypes of the 108 monkeys (Table A in S1
File) and correlated MHC haplotypes with levels of natural antibodies to each of the SIV pep-
tides (Fig 4B and Table B in S1 File). This was based on a relatively small number of monkeys
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available for some of the MHC haplotypes (Table B in S1 File). MHC haplotype M2 at MHC I
or II was significantly correlated with higher natural antibody responses to PCS2 (Fig 4B and
4C, Table B in S1 File). In addition, MHC II of M1 haplotype showed trends of lower antibody
responses to PCS1 (p = 0.0883), PCS2 (p = 0.0833), PCS3 (p = 0.0934) and SIVgag (p = 0.0829)
(Table B in S1 File). Moreover, Monkeys with M2 haplotype at MHC I and MHC II trended to
have higher antibody responses to PCS10 (p = 0.0772) and PCS12 (p = 0.0691), respectively
(Table B in S1 File). These data suggest that host MHC haplotypes may differentially affect nat-
ural antibody responses to SIV antigens. We expect that larger sample sizes may provide more
insight into the correlations between MHC haplotype and antibody responses.
Cross induction of non-PCS antibodies by PCS vaccination
In a pilot experiment to evaluate the immunogenicity of the PCS peptides as a novel vaccine
candidate (Figs 5 and 6), we observed that, besides their natural occurrence, anti-SIV antibod-
ies could also be nonspecifically induced by vaccination with the vaccine targeting PCS (Fig 6).
In the vaccine group (Figs 5A and 6A), eight Mauritian cynomolgus macaques were immu-
nized with PCS peptides delivered by recombinant vesicular stomatitis virus (rVSVpcs) and
nanoparticles (NANOpcs). In the control group (Figs 5B and 6B), six animals were immunized
Fig 1. Natural antibodies to SIV peptide antigens in Mauritian cynomolgus macaques. 108 naïve healthy female Mauritian
cynomolgus macaques maintained in SIV-free facilities were analyzed by Bio-Plex for plasma IgG antibodies to SIV peptide antigens (Ag).
Each black dot indicates one monkey. Red lines represent medians of antibody levels. Abhi: antibody level 2 ng/ml. Frequency of Abhi
monkeys was listed for each Ag type.
https://doi.org/10.1371/journal.pone.0186079.g001
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with the vaccine vector, recombinant vesicular stomatitis virus wild type (rVSVwt) and water.
Antibody responses to SIV peptides were quantified by Bio-Plex antibody assay. As expected,
the PCS vaccination elicited antibody responses to the corresponding PCS peptide antigens
(Fig 6A, Table 2). However, surprisingly, the PCS vaccination also induced antibodies to all
three non-PCS Gag and Env peptides (Fig 6A and 6C, Table 2), although these non-PCS pep-
tides have no sequence overlap with the PCS peptides (Figure A in S1 File). Levels of the non-
PCS antibodies largely correlated with those of PCS antibodies (Table 3). Non-specific effect of
the vaccine vector (rVSVwt and water) was ruled out since the control group monkeys failed
to show the SIV antibody responses (Fig 6B and 6C), while antibodies to VSV (quantified by
ELISA) were significantly induced in these control monkeys (Figure B in S1 File). The Bio-
Plex SIV antibody data were supported by Western blot showing that PCS vaccination led to
the significant increase in monkey antibodies that recognize SIV Gag and Env proteins (Fig
6D). Note that the Env protein does not contain any PCS sequence (Table 1), and the increase
in antibodies to Env protein detected by Western blot (Fig 6D) was consistent with the
increases in antibodies to non-PCS Env peptides detected by Bio-Plex (Fig 6A–6C). These
together confirmed that vaccination against PCS cross-induced antibodies to non-PCS anti-
gens. This observation suggests that a vaccine could lead to “off-target” anti-SIV immune
responses that are not directly to the vaccine itself. The potential impact of such immune
responses needs to be considered in vaccine design and evaluation as well as result
interpretation.
Discussion
Mauritian cynomolgus macaques are emerging as an attractive NHP species for laboratory
research when the traditionally most popular rhesus macaques become limited. Natural
immunity to SIV has been documented in a few NHP species [30]. However, this has not been
Fig 2. Natural antibodies to SIV peptides recognize authentic SIV proteins. The reactivity of SIV peptide-specific antibodies to SIV
proteins was evaluated by Western blot (WB) analysis. Antigens used on these blots were purified recombinant SIV Gag or Env proteins
(NIH AIDS Reagent Program). Plasma antibodies to SIV peptides as in Fig 1 were enriched using SIV peptide-coupled affinity columns. The
enriched antibodies (Monkey SIV Ab) were then tested for reactivity against Gag or Env proteins. Control antibodies (Monkey control Ab)
were protein A/G column-enriched total antibodies from monkey plasma negative (low) for SIV peptide-specific antibodies. M, molecular
weight markers (KDa). The monkey antibody blots (upper row) were stripped and re-probed (lower row) with authentic SIV antibodies,
mouse anti-Gag and Env monoclonal antibodies (Mouse SIV mAb). Blots shown represent three experiments with the same results.
https://doi.org/10.1371/journal.pone.0186079.g002
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Fig 3. Confirmation of antibodies to the SIV peptide antigens as anti-SIV antibodies in the context of SIV infection and
anti-retroviral treatment. (A) 5 monkeys were used in SIV infection and anti-retroviral drug (ARV) treatment experiments. They
had previously been immunized with a vesicular stomatitis virus (VSV) vector, and had not been infected by other viruses
including SIV and Zaire Ebola virus (ZEBOV). Here, they were experimentally infected with SIVmac251, maintained for 25 weeks
and then treated daily with anti-retroviral drugs (ARV). Plasma IgG antibodies to SIV peptide antigens were quantified by Bio-Plex
for time points before and after ARV treatment, at week 0 (-ARV) and week 5 (+ARV) post ARV initiation, respectively. Each line
Novel cynomolgus anti-SIV antibodies
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well investigated in cynomolgus macaques. In this study, we screened natural antibody
responses to SIV antigens in 108 Mauritian cynomolgus macaques. Our study showed the
presence of high levels of natural antibody responses to the SIV antigens including twelve pep-
tides derived from SIV protease cleavage sites (PCS peptides) and three non-PCS Gag or Env
peptides, in some of these monkeys. While the impact of these natural antibody responses on
susceptibility or resistance to SIV infection remains to be studied, the existence of these anti-
SIV antibodies in some of the animals cannot be ignored in HIV vaccine studies using the
Mauritian cynomolgus macaque/SIVmac model. Our data provide important information for
future vaccine projects. For example, the frequencies of monkeys with substantial antibody
responses to SIV antigens can be used to estimate the starting number of monkeys to be
screened to select those with low baseline anti-SIV responses. Therefore, such information will
facilitate the better use of this important animal model.
Higher antibody responses to some of the SIV peptides were demonstrated in the capture
bred group of monkeys than those in the colony bred group, suggesting a possible role of envi-
ronmental factors such as exposure to environmental stress or other unknown retroviruses.
The correlations between monkey MHC haplotypes and antibody responses to specific SIV
antigens shown in our study also suggest that host factors may regulate the antibody responses.
Since the origin of antigens that induced these antibodies and specific factors and mechanisms
that regulate the responses are currently unknown, these topics need to be addressed by exten-
sive future studies.
We observed that monkeys immunized with PCS peptides induced not only antibodies to
the PCS peptides but also antibodies to the non-PCS peptides that have no sequence
represents one monkey, connecting data points before and after ARV. Student’s paired t tests were conducted to assess the
reduction of SIV antibodies by ARV. (B) Plasma SIV viral loads of the five monkeys in A before and after ARV. Viral load reduction
by ARV was confirmed by Student’s paired t test. (C) Levels of plasma IgG to Zaire Ebola virus (ZEBOV) and vesicular stomatitis
virus (VSV) of the five monkeys in A were quantified by ELISA. OD, optical density. No significant difference was found in either
case between before and after ARV by Student’s paired t test.
https://doi.org/10.1371/journal.pone.0186079.g003
Fig 4. Environment and host factors may have an impact on natural antibody responses to SIV antigens. (A) Natural
antibody responses to SIV antigens were compared between capture bred (14 animals) and colony bred (94 animals) monkeys.
Data are mean ± SEM of plasma IgG concentrations. Significant difference between the two sub-groups was determined for
antibodies to PCS1, PCS7, PCS11 and SIVgag by Student’s t test: *** p < 0.001 and ** p < 0.01. No difference was found for
antibodies to the other antigen types (data not shown). (B) MHC I M2 and MHC II M2 haplotypes correlate with higher
frequencies of monkeys with stronger natural antibody responses to PCS2. Bars represent frequencies of monkeys with 2 ng/
ml plasma IgG to PCS2 in those with or without M2 haplotype of MHC I or MHC II. Correlation analysis was performed using
Fisher’s exact test: * p < 0.05. (C) MHC I M2 and MHC II M2 haplotypes correlate with higher levels of natural antibodies to
PCS2. Bars represent mean ± SEM of concentrations of plasma IgG to PCS2. Significant difference between MHC I M2 and
MHC I non-M2 groups or between MHC II M2 and MHC II non-M2 groups was determined by Student’s t test: *** p < 0.001.
https://doi.org/10.1371/journal.pone.0186079.g004
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homologies with PCS peptides. There might be two potential explanations based on current
knowledge in the field. First, it is possible that although there is no similarity in primary struc-
tures between PCS and non-PCS peptides, they may share similar secondary structures that
contribute to cross-reactivity [31]. The second possibility could be the presence of endogenous
retroviral sequences in primate genomes [32–43]. Some of the endogenous retroviral
sequences sharing homology with non-PCS peptides might be expressed in response to stimuli
such as vaccination conditions or environmental stress (in the case of natural antibody induc-
tion), and result in antibody responses [37, 44–53]. While these possibilities can be explored in
future studies, our study showed that a vaccine aimed at specific sites of SIV could hit addi-
tional targets. This may potentially impact on the outcome of vaccination and hence need to
be considered in vaccine design and evaluation as well as result interpretation.
The term of “off-target effect” was recently used by the vaccine field to describe the phe-
nomena where some vaccines can lead to a variety of unexpected, non-specific responses or
outcomes (immunological or non-immunological) other than what are expected based on the
intended immune responses specifically targeting the immunogens of interest [54]. The mech-
anisms appear to be complex and heterogeneous and remain to be understood. Off-target
immune responses similar to those observed in our study have not been previously reported in
the HIV vaccine field. Part of the reason might be that the classical HIV vaccine approach in
most cases used large viral proteins as immunogens and all immune responses targeting the
Fig 5. PCS vaccination design. Animals were primed and boosted on indicated dates. rVSVpcs:
recombinant vesicular stomatitis viruses (rVSV) expressing peptides derived from SIV protease cleavage
sites (PCS peptides), NANOpcs: PCS peptides packaged in nanoparticles (NANO), rVSVwt: rVSV wild type
(control virus), and Water: NANO vehicle control. Vaccine production, dose and route of administration are
detailed in Materials and Methods.
https://doi.org/10.1371/journal.pone.0186079.g005
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Fig 6. Cross induction of non-PCS antibodies by PCS vaccination. (A) Vaccine group: Eight female
Mauritian cynomolgus macaques received a prime with rVSVpcs, first boost with NANOpcs and second boost
with rVSVpcs/NANOpcs. Antibodies to SIV peptides were quantified by Bio-Plex. Each panel represents one
monkey. Graphs show concentrations of plasma IgG to PCS peptides (black) as well as non-PCS peptides (red)
at weeks after the second boost. (B) Control group: Six monkeys received vaccine vehicles including a prime
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with rVSVwt, first boost with water and second boost with rVSVwt/water, and were analyzed for antibodies. (C)
Statistical analysis of antibody responses to non-PCS peptides in A and B. Bars represent normalized
mean ± SEM. Student’s t test confirmed significant induction of non-PCS antibodies in the vaccine group (*
p < 0.05, ** p < 0.01 and *** p < 0.001), but not in the control group. (D) PCS vaccination led to enrichment of
monkey plasma antibodies that recognize purified recombinant Gag and Env proteins. Western blot membranes
containing recombinant SIV proteins were first probed with plasmas of a PCS-vaccinated monkey. Plasmas
from time points of Baseline sampling (indicated as “B” in the graphs) and one week after the second Vaccine
boost (indicated as “V” in the graph) were compared for levels of IgG antibodies to the SIV proteins. The
membranes were later stripped and re-probed with standard mouse anti-Gag or Env monoclonal antibodies. For
quantitative analysis, monkey anti-SIV antibody levels were defined as band intensities with monkey plasma
normalized to the corresponding band intensities with standard mouse antibodies. Bar graphs represent
mean ± SEM of three independent experiments. Significant induction of antibodies to authentic SIV proteins
Gag and Env by PCS vaccination was confirmed by Student’s paired t test (* p < 0.05).
https://doi.org/10.1371/journal.pone.0186079.g006
Table 2. PCS vaccine cross-induces antibody responses to non-PCS that correlate with antibody responses to PCS.
ID Wk PCS1 PCS2 PCS3 PCS4 PCS5 PCS6 PCS7 PCS8 PCS9 PCS10 PCS11 PCS12 SIV gag SIV env1 SIV env2
AM260 0 1.34 2.07 1.60 2.16 2.74 1.48 1.45 2.11 1.09 0.96 186.17 1.16 2.13 2.31 2.22
1 16.53 41.94 14.14 5.98 8.43 17.57 19.58 19.88 18.70 25.35 247.65 23.48 41.29 46.33 19.63
2 8.06 21.59 7.40 3.79 5.76 9.26 10.25 10.04 8.92 12.02 309.93 11.27 20.01 23.44 10.03
3 3.00 7.45 3.07 2.60 3.36 3.42 3.94 4.12 3.38 3.91 213.00 3.76 6.87 8.02 4.07
AM672 0 49.56 1.36 1.56 3.79 1.67 1.40 45.23 2.02 1.33 0.87 5.40 1.32 10.44 2.27 2.04
1 56.29 2.20 1.94 4.16 2.49 1.93 46.43 2.48 1.57 2.06 7.16 1.93 13.64 3.57 2.65
2 55.97 2.33 1.89 3.30 2.14 2.02 37.58 2.60 1.56 1.93 8.82 1.98 15.21 3.62 2.38
3 60.08 1.16 1.42 8.55 2.12 1.24 17.27 1.76 1.54 1.05 9.32 2.03 13.67 1.88 2.32
AT789 0 2.34 1.32 1.32 1.14 3.54 1.31 6.03 1.53 1.16 0.94 1.00 1.23 1.56 2.13 1.56
1 4.00 6.71 2.78 1.82 4.96 3.08 9.94 3.55 3.08 5.13 2.69 4.51 7.56 8.46 3.64
2 3.93 6.42 2.43 1.83 5.39 3.00 10.12 3.40 3.18 5.00 2.82 4.31 7.25 8.60 3.00
3 2.37 2.14 1.51 1.40 6.85 1.58 6.94 1.67 1.60 1.73 1.32 1.76 2.59 3.53 1.89
AV187 0 0.47 0.52 0.62 2.03 0.56 0.86 9.67 1.08 0.58 0.29 0.60 0.60 0.56 0.87 1.18
1 1.29 1.33 1.43 1.49 1.29 1.26 8.84 1.64 1.17 1.17 0.96 1.57 1.63 1.93 2.09
2 2.95 6.11 2.65 1.67 1.76 3.17 11.80 3.64 3.32 3.66 2.82 3.91 5.85 7.04 4.47
3 1.15 2.07 1.20 1.17 1.09 1.29 9.05 1.80 1.33 1.29 1.14 3.70 2.01 2.68 1.94
AV429 0 0.87 1.23 1.33 2.36 1.85 1.90 0.94 2.20 0.67 0.47 16.44 0.74 0.93 14.12 1.73
1 3.47 7.38 3.05 3.02 2.47 4.33 3.51 4.42 3.28 5.66 22.20 4.30 7.96 22.42 2.76
2 2.91 7.44 2.78 3.05 2.32 3.88 3.70 4.15 3.11 5.17 24.97 4.09 7.94 22.46 2.92
3 1.48 3.72 1.82 2.33 1.54 2.84 1.85 2.52 1.69 2.49 25.27 2.14 3.83 18.26 1.98
BM524 0 2.03 1.32 1.47 1.36 1.98 1.80 0.76 2.11 0.89 0.60 1.97 0.81 1.33 1.69 4.71
1 12.93 27.91 9.85 4.09 5.60 11.15 14.76 13.15 12.15 20.92 12.05 17.64 30.84 32.95 16.16
2 6.51 12.75 4.69 2.34 3.32 5.55 6.76 6.60 5.60 9.15 6.44 7.33 13.56 15.53 9.14
3 2.95 3.76 1.87 1.48 2.03 2.22 1.72 2.47 1.64 1.96 3.18 1.96 3.49 4.20 5.61
BM576 0 2.69 2.05 2.18 3.67 2.52 1.80 1.18 2.97 1.14 1.14 9.88 1.16 1.96 5.78 2.38
1 7.94 11.42 5.40 5.80 4.71 5.57 6.25 7.41 5.90 11.00 14.28 8.33 14.18 19.35 4.96
2 6.46 9.84 4.76 4.65 3.48 4.91 5.40 6.20 5.02 9.15 13.81 6.92 11.74 16.42 3.96
3 2.86 4.20 2.44 2.33 1.76 2.47 2.16 3.34 2.34 3.54 11.25 3.00 4.74 9.06 2.29
BM795 0 1.25 1.27 1.11 1.05 1.98 1.35 18.19 1.53 1.54 0.78 1.57 0.87 4.47 2.80 1.78
1 11.89 21.09 8.68 3.14 5.14 9.71 26.65 11.04 12.11 17.44 12.07 13.80 28.00 27.26 10.98
2 8.60 15.71 6.25 2.78 3.98 7.13 21.25 7.86 8.71 12.08 8.55 10.09 21.63 21.01 8.03
3 2.46 3.65 2.09 1.75 2.52 1.78 18.38 2.54 2.98 2.58 2.60 2.28 7.23 7.04 2.60
Plasma IgG (ng/ml) to SIV peptides at weeks (Wk) after the second boost in PCS-vaccinated monkeys (Fig 6A).
https://doi.org/10.1371/journal.pone.0186079.t002
Novel cynomolgus anti-SIV antibodies
PLOS ONE | https://doi.org/10.1371/journal.pone.0186079 October 5, 2017 15 / 20
large molecules would be perceived as “on-target”. In our case of testing novel vaccine candi-
dates based on short peptides, we analyzed antibody responses focusing on the short peptides,
and included additional non-target peptide antigens in the analysis, making it easier to observe
an “off-target” effect.
In conclusion, our findings of natural and vaccine cross-inducible SIV antibodies in Mauri-
tian cynomolgus macaques provide useful new information for HIV vaccine study using this
increasingly important NHP model. The presence of these novel immune responses should be
considered to achieve better animal selection, experimental design and result interpretation.
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